Neurofibromatosis type 1 (NF1) is a common genetic disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumors (MPNST). In this study, we report the modulation of murine and human MPNST cell growth by the fatty acids docosahexaenoic acid (DHA) and arachidonic acid (AA). DHA demonstrated a tendency to stimulate cell growth at low doses and induce apoptosis at high doses, paralleled by the activation of ERK and caspase-3. Furthermore, high-dose DHA reversed the stimulation of MPNST cell growth by a number of growth factors suggested to have a pathogenic effect in NF1 and inhibited MPNST growth in vivo. AA was found to have a reciprocal activity in vitro, stimulating MPNST cell growth at comparable concentrations and reducing DHA activation of ERK. These findings introduce fatty acids as a possible regulator of MPNST development in NF1 patients.
Introduction
Neurofibromatosis type 1 (NF1) is a common neurogenetic disorder (1 : 3500) with an autosomal dominant mode of transmission and highly variable expressivity (Huson et al., 1988) . The pathogenesis of NF1 is linked to loss of the NF1 gene encoding the tumor suppressor neurofibromin, an activator of intrinsic Ras GTPase (DeClue et al., 1991 (DeClue et al., , 1992 Gutmann et al., 1991) . Patients with NF1 experience a high incidence of multiple tumor types, most notably neurofibromas and malignant peripheral nerve sheath tumors (MPNST).
Neurofibromas tend to develop in periods of hormonal and growth factor shifts such as puberty and pregnancy (Hall, 1981; Huson, 1994; Dugoff and Sujansky, 1996) . It is well known that dermal and plexiform neurofibromas can grow larger during pregnancy and regress in the postpartum period (Swapp and Main, 1973; Isikoglu et al., 2002) . A high percentage of neurofibromas have been shown to express progesterone receptors, suggesting progesterone as a candidate for tumor stimulation during pregnancy (McLaughlin and Jacks, 2003) . In addition to the potential hormonal effects on tumorigenesis, a number of growth factors are also upregulated with loss of neurofibromin and have been suggested to contribute to the growth of neurofibromas and MPNST (Mashour et al., 2001 (Mashour et al., , 2004 Kurtz and Martuza, 2002) . These include platelet-derived growth factor (PDGF) (Badache and DeVries, 1998) , basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) (Li et al., 2002) .
Although hormone and peptide growth factors have been studied in NF1, there has been no investigation of fatty-acid modulation of NF1 tumor growth. Expression profiling in Nf1À/À Schwann cells revealed dramatic induction of brain fatty-acid binding protein (FABP-7) (Feng et al., 1994; Kurtz et al., 1994; Miller et al., 2003) , a protein demonstrated to bind docosahexaenoic acid (DHA) with high affinity (Xu et al., 1996) . DHA is the long-chain metabolite of the essential fatty acid linolenic acid, an omega-3 fatty acid. DHA has been demonstrated to have a critical role in the development of the brain and visual system, and deficiency in primates results in polydipsia, visual impairment, and abnormal neural membrane composition (Neuringer et al., 1984 (Neuringer et al., , 1986 Reisbick et al., 1990) . In addition to its role in development and maintenance of normal tissues (Holman, 1998) , DHA has been demonstrated to have antitumorigenic effects. Individuals with diets high in DHA have a lower incidence of various cancers, and DHA has been shown to slow the growth of cancer xenografts and improve the efficacy of chemotherapy (Hardman, 2002) . Multiple mechanisms have been proposed for this effect, including suppression of mitosis, induction of apoptosis, inhibition of COX-2, and induction of differentiation (Hardman, 2002) . DHA has also been shown to decrease levels of GTP-bound Ras, as well as interrupt the insertion of Ras into the plasma membrane (Collett et al., 2001) . Interestingly, DHA has been shown to inhibit the Ras-GAP activity of neurofibromin (Golubic et al., 1998) . DHA can also modulate the effects of estrogens and androgens on hormone-responsive tumors (Chung et al., 2001) and has been shown to reverse EGF-induced cell transformation (Liu et al., 2001) .
In the present study, we report a bimodal effect of DHA on cell growth and apoptosis. Furthermore, we demonstrate that DHA dramatically reverses growth stimulation induced by EGF, PDGF-b, bFGF, and insulin-like growth factor 1 (IGF-1). Consistent with other studies in different tumor types, we show the reciprocal activity of DHA and arachidonic acid (AA), an omega-6 fatty acid. This study introduces the relevance of fatty-acid modulation of peripheral nerve tumors and proposes a role for DHA in the pathogenesis of NF1.
Results

High-dose DHA induces apoptosis of murine and human MPNST cells
To test the effects of DHA on MPNST-derived cells, human (S520, S462, S805) and murine (32-5-30, 39-2-11) MPNST cells were exposed to DHA at physiologic concentrations as found in maternal plasma (Ruyle et al., 1990) . At low doses of 3 mg/ml, cell numbers of mouse cell line 32-5-30 and human MPNST cell lines increased significantly by 119-209% at day 3 ( Figure 1a) . No effect was seen on NF1 þ /À and normal human and mouse dermal fibroblasts, and on mouse MPNST line 39-2-11. MPNST cell line 39-2-11 is the most tumorigenic cell line out of a panel of six independent lines, while 32-5-30 was the least tumorigenic line (data not shown), indicating a loss of sensitivity to DHA with enhanced tumorigenic potential. At 30 mg/ml of DHA, a high proportion of murine MPNST cells are dead, with less dramatic effect on human MPNST cells at this concentration. The differences between treated and untreated cells were significant at (Po0.02, two-sided t-test), except for cell line S520, for which a significant difference was found between the low-and high-dose treatment groups only (Po0.05, two-sided t-test). (32-5-30, 39-2-11) and human (S805, S462, S520) MPNST cells, and of NF1 þ /À and wild-type mouse and human primary dermal fibroblasts. Cells were exposed to DHA or albumin for 3 days in serum-free conditions. (Asterisks: Significance between treatment groups and untreated control cells; **Po0.002, *Po0.02, two-sided t-test. Bars without asterisks show no significant difference between treated and untreated groups. There is a significant difference between the 30 and 3 mg/ml groups in S520 and human NF þ /À fibroblasts: Po0.045) (b) Immunofluorescence of 6-CF (green) or annexin (red) in murine 39-2-11 cells treated with either DHA (upper panel) or albumin carrier (lower panel). Cells were cultured in serum-free media for 24 h, DHA or control media was added, and apoptosis was measured at 24 h. (c) Western-blot analysis of activated caspase-3 and b-actin in mouse (39-2-11) and human (S520) MPNST-derived cell lines. Cells were exposed to DHA and AA for 7 h under serum-free conditions There was no effect on cell numbers of normal human and mouse dermal fibroblasts. A slight effect on NF1 þ /À dermal human fibroblasts was observed when compared to untreated control cells (P ¼ 0.085, two-sided t-test), while the difference in cell number between high-and low-dose DHA treatment groups was significant at P ¼ 0.045 (Figure 1a) .
To establish the mechanism of cell death, we exposed mouse cell line 39-2-11 and 32-5-30 to DHA at 60 mg/ml and albumin solution for 24 h in serum-free medium and measured the presence of apoptotic and vital cells using annexin V and 6-CF, respectively. Markers of early apoptosis were observed in >80% of DHA-treated cells, while o5% of control cells were apoptotic ( Figure 1b ). Western analysis confirmed the induction of apoptosis via the caspase pathway by DHA but not by AA in all human and mouse MPNST cells as shown for cell lines S520 and 39-2-11 ( Figure 1c ). When the human cell line S462 was tested for induction of apoptosis by DHA using annexin V and 6-CF, about 40% of DHA-treated cells were apoptotic, while fewer than 5% of untreated cells died (data not shown).
DHA reverses growth factor stimulation of MPNST cells, and has reciprocal activity with AA
We tested the effect of DHA in combination with growth factors known to stimulate MPNST growth. In cell line 39-2-11, EGF and PDGF-b induced over a threefold increase in cell growth, while bFGF and IGF-1 induced over a twofold increase compared to control at day 6. DHA (30 mg/ml) completely reversed the growth stimulation of all growth factors tested, and reduced cell numbers to levels comparable to those found with DHA alone (Figure 2a ). The reduction of cell numbers in EGF-stimulated cells was dose dependent (Figure 2b ), even in the presence of 0.5% FCS. Comparable levels of growth factor stimulation and DHA inhibition were also found with cell line 32-5-30 (not shown).
DHA and AA have often been shown to have reciprocal activity in the modulation of cancer cells (Hardman, 2002) . In order to test this reciprocal effect on MPNST cells and establish specificity of fatty-acid modulation of MPNST cell growth, we compared the effect of DHA and AA at 30 mg/ml on MPNST cell death and proliferation. While DHA led to almost complete cell death, AA led to a twofold increase in proliferation (Table 1) . We further tested the effect of 30 mg/ml AA on growth factor stimulation of MPNST cell line 39-2-11. AA had no effect on EGF and IGF-1, and attenuated the effect of bFGF ( Figure 2c ). AA had a marked synergistic effect on PDGF-b stimulation, inducing a six-fold increase in growth compared to a three-fold increase with PDGF-b alone ( Figure 2c ). Thus, while DHA consistently reverses growth factor stimulation, AA has a variable effect.
It has been shown that the ratio of DHA and AA may have an effect on tumorigenesis in various cancers (Hardman, 2002) . We investigated this phenomenon by treating 32-5-30 and 39-2-11 cells with various combinations of low-dose (3 mg/ml) and high-dose (30 mg/ml) DHA and AA (Table 1 ). In conditions of high-dose DHA, neither dose of AA could stimulate the growth of MPNST cells, although the presence of AA attenuated DHA inhibition of cell line 32-5-30. In conditions of low-dose DHA, both doses of AA led to stimulation of cell growth beyond the effect of either high dose AA Effect of DHA (30 mg/ml) on growth factor stimulation of murine 39-2-11 MPNST cells incubated for 6 days, with change of media at 3 days. The differences between the growth factor alone and growth factor plus DHA groups are significant (Po0.0007, t-test). (b) Dose-response assay of DHA on EGF and 0.5% FCS stimulation of murine 39-2-11 MPNST cells. Asterisks: Po0.01 as compared to EGF alone; asterisk in brackets: P ¼ 0.07 (t-test). (c) Effect of AA (30 mg/ml) on growth factor stimulation of murine 39-2-11 MPNST cells. Significant differences are marked by asterisks: Po0.02 (t-test)
Fatty-acid regulation of NF1 tumor growth GA Mashour et al or low-dose DHA alone. At these concentrations, there was no apparent dose-dependence of AA in stimulation. In summary, it appears that at comparable doses of AA and DHA, the levels of DHA in the media control the overall cell growth pattern, even in the presence of growth factors.
DHA induces ERK phosphorylation and caspase activation in MPNST cells
It has been suggested that DHA may act via inhibition of Ras in colon cancer cells (Collett et al., 2001 ). Here we investigated Ras-GTP levels, and phosphorylation of the downstream signaling molecules MAP kinase/ERK in response to EGF and DHA in human MPNST cells S520, S462 and mouse MPNST cells 39-2-11, 32-5-30. As expected, EGF (20 ng/ml) strongly induces ERK phosphorylation in all MPNST cells studied. Surpri singly, DHA also caused increased P-ERK levels, and in combination with EGF elevated the EGF effect in all cell lines (Figure 3a) . We did not detect a difference in Ras-GTP levels between EGF-and EGF/DHA-treated cells and control cells (data not shown).
The effects of AA in combination with EGF and DHA on ERK and caspase-3 were elucidated in cell lines 39-2-11 and 32-5-30 with similar results for both (data shown only for 39-2-11). At 30 mg/ml, DHAinduced ERK phosphorylation was reversed by AA (30 mg/ml). This reversal by AA was blocked by the addition of EGF, with and without DHA, to the cells (Figure 3b) . DHA (30 mg/ml) induced activation of the key apoptotic enzyme caspase-3, an effect that was not blocked by EGF and only partially inhibited by AA. In contrast, although 3 mg/ml DHA resulted in ERK phosphorylation, no caspase activation was detected (Figure 3b ). These data indicate that DHA activates two pathways in MPNST cells: MAP kinase/P-ERK pathway is activated at high and low concentrations, while the apoptotic pathway via caspase-3 is activated only at high concentrations.
Tumor growth inhibition by DHA
Subcutaneous tumors from mouse MPNST cell line 32-5-30 were grown in nude mice and directly injected with DHA, AA, or albumin carrier (n ¼ 6 in each group). A significant difference in tumor size between the DHA and albumin group was detectable starting at 13 days post-treatment (Po0.005, t-test) and continued until the end of the experiment (Figure 4a) . A signifi cant difference between the DHA and AA groups was detectable at 20 days post-treatment (Po0.009). Figure 3 Western-blot analysis of ERK phosphoprylation and caspase-3 activation in MPNST-derived cells in response to EGF, DHA, and AA. (a) ERK-phosphorylation in human S520 and mouse 39-2-11 cells. Cells were pre-incubated with DHA for 1 h before EGF was added for 5 min and 1 h, respectively, under serum-free conditions. b-actin was used as a loading control. Results for cell lines S462 and 32-5-30 are essentially the same and not shown. (b) Caspase-3 activation of murine 39-2-11 MPNST cells in response to EGF, DHA, and AA. Cells were incubated for 7 h with the factors as indicated under serum-free conditions. b-actin was used as a loading control
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Tumors treated with AA were not significantly different from controls, except for two time points at days 18 and 20 (Po0.02). Survival was significantly increased in the DHA-treated group compared to the AA and albumin control groups (P ¼ 0.0007 and 0.0004, respectively; log-rank test). There was no difference in survival between the AA and albumin groups (Figure 4b ).
DHA receptor expression in neurofibromas and MPNST
Since DHA binds with high affinity to the intracellular binding protein FABP-7 (Xu et al., 1996) , we analyzed its expression in human and mouse peripheral nerve, neurofibromas, MPNST, and MPNST-derived cells.
RT-PCR analysis revealed FABP-7 mRNA expression in human neurofibroma-derived Schwann cells, MPNST-derived cells, but not in normal human Schwann cells and nontumor cell S811 from an NF1 patient (Figure 5a ). FABP-7 mRNA expression was also detected in 6/6 mouse Nf1:p53 MPNST cell lines; however, expression was reduced in tumor grafts derived from these cells (Figure 5b ).
Protein expression was shown by immunohistochemistry in sciatic nerve of Nf1 þ /À mice, but not in wild-type mice, and in three of seven plexiform neurofibromas (Figure 5c-e) .
Discussion
The present study is the first to demonstrate the fattyacid modulation of tumor cell types relevant to the neurofibromatoses and the first to suggest a dietary factor of potential relevance to the natural history of NF1. The omega-3 fatty acid DHA was shown to stimulate cell growth of a majority of Nf1:p53 MPNST cells at low doses with an associated activation of the ERK pathway and to induce apoptosis at high doses. Apoptosis induction was accompanied by activation of caspase-3, indicating that this pathway may be involved in mediating the DHA effect, although other pathways cannot be excluded. A high physiologic dose of DHA completely reversed cell growth stimulation by a number of growth factors with demonstrated pathogenic effects in tumors of NF1, and inhibited tumor growth in vivo. The DHA concentrations of 30 and 60 mg/ml used in this study are well within the normal physiologic range, and even much higher levels have been observed (Ruyle et al., 1990; Theobald et al., 2004) .
It has been demonstrated that DHA can decrease levels of GTP-bound Ras, as well as interrupt the insertion of Ras into the plasma membrane (Collett et al., 2001) . While DHA-mediated inhibition of Ras activation by growth factors was an attractive hypothesis, at these concentrations DHA does not appear to modulate Ras in the cell lines used. A provocative result is the activation of ERK in MPNST cells by DHA, accompanied by apoptotic DHA effects. One possible explanation may be that DHA-mediated ERK activation, perhaps through interaction with membrane rafts (Shaikh et al., 2003) , activates a downstream pathway leading to apoptosis. A similar effect has indeed been described for retinoic acid (Pettersson et al., 2004) in breast cancer cells and for DHA in oligodendroglial cells (Brand et al., 2001) . This DHA effect is likely to act independently from the observed stimulation of ERK and cell proliferation by EGF in MPNST cells (Li et al., 2002) .
As with other cancer cell types, DHA and AA were found to have reciprocal activities on MPNST cell growth in vitro, with AA stimulating MPNST cell growth alone and in combination with DHA. AA appeared to attenuate the effect of DHA tumor inhibition and was demonstrated to reverse the effects of DHA on ERK phosphorylation, as well as moderately reduce DHA-mediated caspase-3 activation. These phenomena may explain the antagonism of DHA and AA seen on cell growth. AA did not, however, stimulate tumor growth in vivo. This may reflect the variable effect of AA on growth factor stimulation. AA was shown to inhibit bFGF in vitro, which may have had a more prominent effect in vivo than it had for the stimulation of MPNST cell growth in vitro. The role of AA in MPNST tumorigenesis warrants further investigation, especially considering the potentially therapeutic role of COX-2 inhibitors on tumors with a similar fatty-acid modulation (Dempke et al., 2001) .
DHA is crucial to the development of neural structures in the fetus. The fetus thus has a high demand and it has been suggested that DHA is delivered to the developing fetus by erythrocytes (Ruyle et al., 1990) , as maternal erythrocyte DHA levels decrease during pregnancy (Ghebremeskel et al., 2000) . The transfer of DHA to the fetal circulation could account for the observation that neurofibromas grow in size and number during pregnancy (Dugoff and Sujansky, 1996) . Our data on MPNST demonstrate a tendency for low-dose DHA to promote growth and high-dose DHA to inhibit growth, even in the presence of AA. A similar process may be true for neurofibroma growth, as the DHA receptor FABP-7 was found to be expressed in Schwann cells of embryonic peripheral nerve (data not shown), adult Nf1 þ /À sciatic nerve tissue, and in three of seven clinical neurofibroma samples. As DHA leaves the maternal circulation, the pre-existing maternal neurofibromas and in situ lesions may transform from a state of quiescence to a state of growth. The maternal loss of DHA may also create a more permissive environment for growth factors such as EGF, PDGFb, bFGF, and IGF-1 to stimulate tumorigenesis. While the demonstration of progesterone receptor expression in neurofibromas is potentially relevant for tumori genesis during pregnancy (McLaughlin and Jacks, 2003) , the role of fatty-acid redistribution should also be explored. FABP-7 has been shown to be upregulated in neurofibromin-deficient Schwann cells and is a receptor for DHA (Xu et al., 1996; Miller et al., 2003) . Here, we demonstrate that FABP-7 expression is enhanced in human neurofibromas and MPNST cells in vitro, supporting the data of Miller et al. We found, however, that tumor grafts of Nf1:p53 MPNST cell lines had variable expression of FABP-7, with aggressive cell lines losing expression in vivo. The variable MPNST expression of FABP-7 in vivo suggests that other mechanisms may be involved in DHA-mediated tumor regression in vivo.
In conclusion, we introduce fatty-acid modulation as a mechanism of tumor cell regulation in MPNST, and suggest a potential role for DHA in the pathogenesis of NF1. DHA and its receptor FABP-7 warrant further investigation in the natural history and therapy of NF1.
Materials and methods
Fatty-acid preparation
DHA and AA (Sigma) were each mixed with 5% delipidized albumin solution (Sigma) in DMEM to a final concentration of 600 mg/ml, and incubated for 1-2 h at 371C. Fatty-acid solutions were aliquoted, stored at À801C, and thawed immediately before use. Antioxidants were not added in addition to albumin/DMEM for mixing, storage or subsequent experiments.
Cell culture and proliferation assays
Mouse Nf1:p53 MPNST cell lines 39-2-11 and 32-5-30 were a gift of Louis Parada (University of Texas). Human NF1:P53 MPNST cell lines S520 (2) and S462 (6) were derived from MPNST and genotyped as described (Frahm et al., 2004: Codes from this publication are in brackets). MPNST-derived cell line S805 was NF1À/À and p16À/À, while no p53 was detected by screening of exons 4-8 in this cell line (S Frahm, data not shown). Human cell line S811 was derived from an MPNST. However, mutation and karyotype analysis of this cell line revealed its nontumor origin. Human and murine primary dermal fibroblasts were obtained from Nf1 þ /À and wild-type mice, and from skin of an NF1 patient and a healthy subject. All cells were cultured in DMEM (Invitrogen) supplemented with 10% fetal calf serum (FCS) (Invitrogen) and penicillin/streptomycin.
For proliferation assays, cells were plated in 24-well plates at 20 000 cells/well for 3-day growth assays and 10 000 cells/well for 6-day growth assays in complete growth medium. Cells were allowed to adhere, and were thereafter cultured in serum-free media for 24 h. Media supplemented with albumin solution, DHA and AA, or growth factors EGF (Sigma), PDGF-b (Sigma), bFGF (Invitrogen), and IGF-1 (Invitrogen) were added and cells were allowed to incubate at 371C. Cells were trypsinized and counted with Trypan blue after 3 days. For 6-day assays, media were changed on day 3, and cells were counted on day 6. Concentrations and combinations of the individual factors are as described in figure legends.
Apoptosis detection
Apoptosis in cell culture was detected using the annexinCy3.18 and 6-carboxyfluorescein diacetate (6-CF) system (Sigma). To induce apoptosis, cells were cultured in serumfree DMEM for 24 h, and then treated with either DHA at 30 mg/ml or albumin solution at the same dilution. After 24 h of incubation, cells were harvested and stained by double immunofluorescence for annexin and 6-CF according to the manufacturer's protocol.
Western analysis
Approximately 2 Â 10 5 cells were seeded in each well of a 12-well dish, allowed to adhere in complete growth medium for 16 h, and cultured in serum-free DMEM for 24 h before treatment with EGF, DHA, or AA as described in the figure legends. Cells were lysed at 5 min, 1 and 7 h post-treatment in the appropriate lysis buffer supplemented with protease inhibitors leupeptin, aprotinin, and PMSF (Sigma). Lysates were immediately snap-frozen in liquid nitrogen and equal amounts of protein were loaded on a 12-15% SDS gel for electrophoresis. Western analysis was subsequently performed using anti-P-ERK/ERK, anti-ERK (Upstate), anti-caspase-3 (Cell Signalling), and anti-beta-actin (Santa Cruz) antibodies using a horseradish peroxidase -labeled goat anti-rabbit secondary antibody (Amersham) and ECL-chemiluminescence detection system (Amersham).
Tumor growth assays
Nude mice were injected subcutaneously with the mouse MPNST cell line 32-5-30 at 10 5 cells/mouse. When tumors reached the size of approximately 100 mm 3 , the mice were randomly assigned to three groups of six mice each. The tumors in the experimental group were injected with 10 ml DHA (30 mg/ml), and the tumors in the control groups with either 10 ml AA (30 mg/ml) or albumin solution. Tumors were injected and measured every other day. Mice were killed when tumor size reached 2 cm in one dimension.
RT-PCR analysis
RNA was prepared from equal cell numbers or tissue volumes using Trizol reagent (Life Technologies) for cDNA transcription with oligo-dT primers and Superscript (Gibco-BRL). Human b-actin primers (5 0 -AGCGGTTCCGCTGCCTGA-3 0 and 5 0 -GGACTTCCTGTAACAATG-3 0 ), mouse b-actin primers (Invitrogen), and human/mouse FABP-7 primers (5 0 -GGCGTGGGCTTTGCCACT-3 0 and 5 0 -TGCCATCCT TAATTTCTC-3 0 ) were used in PCR reactions. In all, 35 cycles of 941C 1 min; 551C 1 min, and 721C 1 min were performed and products analyzed on a 1.0% agarose gel.
Immunohistochemistry
Paraffin-embedded human neurofibroma tissue sections were prepared for immunohistochemistry as described previously (Mashour et al., 2001) . Anti-FABP-7 antibody (1 : 3000) was applied for 20 min at 501C (kindly provided by Thomas Mu¨ller, MDC Berlin, Germany), and secondary biotinylated goat anti-rabbit antibody in PBS/2% BSA was applied for 20 min at room temperature. For detection and visualization, the ABC system (Vector) was used according to the manufacturer's protocol with 0.1 mg/ml DAB as substrate. Mouse tumors and normal nerve were removed and snapfrozen, sections were fixed in 4% paraformaldehyde, washed in PBS, and immunohistochemistry was performed as described previously (Mashour et al., 2001) .
Abbreviations AA, arachidonic acid; DHA, docosahexaenoic acid; FABP, fatty acid binding protein; MPNST, malignant peripheral nerve sheath tumor; NF1, neurofibromatosis type.
